Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Penumbra, Inc. (PEN) SEC filings page provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents include current reports on Form 8-K, annual and quarterly reports, and other materials that together outline Penumbra’s financial condition, major corporate events and obligations as a NYSE-listed issuer.
Among the most significant recent filings is a Form 8-K dated January 15, 2026, in which Penumbra reports entry into an Agreement and Plan of Merger with Boston Scientific Corporation and a Boston Scientific subsidiary. The filing describes the structure of the merger consideration, the mix of cash and Boston Scientific common stock, and the conditions required for closing. It also states that, if the merger is consummated, Penumbra’s securities will be delisted from the New York Stock Exchange and deregistered under the Securities Exchange Act of 1934 as promptly as practicable after the effective time.
Other Form 8-K filings highlighted here include results of operations and financial condition for specific quarters, where Penumbra furnishes earnings press releases as exhibits. These filings discuss revenue growth, gross margin, operating margin and the use of non-GAAP measures such as constant currency revenue, non-GAAP income from operations and adjusted EBITDA. The company explains how these non-GAAP metrics are calculated and why management considers them useful for assessing underlying business performance.
Additional 8-Ks address corporate governance and leadership changes, such as the appointment of a new company president and related compensation arrangements. These filings provide detail on board and executive decisions, equity awards and related person transactions, all within the framework of SEC disclosure requirements.
Through this page, users can follow Penumbra’s formal reporting on material events, financial results and the proposed merger with Boston Scientific. Stock Titan’s platform associates each filing with AI-powered summaries designed to explain the core points of lengthy documents, helping readers quickly understand items such as merger terms, earnings highlights, and key governance changes without having to parse every line of the underlying text.
For deeper research, investors can review the full text of Penumbra’s 10-K and 10-Q reports via the SEC’s EDGAR system, while using the summaries and context on this page as a guide to the most important disclosures affecting PEN and its anticipated transition to a wholly owned subsidiary of Boston Scientific.
Penumbra, Inc. agreed to be acquired by Boston Scientific Corporation through a cash-and-stock merger where Penumbra will become a wholly owned subsidiary. At closing, each Penumbra common share will be converted into the right to receive either $374.00 in cash or 3.8721 Boston Scientific common shares, with elections subject to proration so that approximately 73.26% of shares receive cash and 26.74% receive stock.
The deal requires approval by a majority of Penumbra’s voting shares, antitrust and other regulatory clearances, effectiveness of Boston Scientific’s Form S-4, and NYSE listing approval for the stock consideration. Either side may owe a termination fee under certain conditions, including $525 million payable by Penumbra and $900 million payable by Boston Scientific if specified antitrust-related conditions are not met. If the merger closes, Penumbra’s stock will be delisted and deregistered, and the companies have issued and plan further SEC filings and proxy materials describing the transaction.
Penumbra Inc. director Harpreet Grewal reported a small insider sale of common stock. On January 6, 2026, Grewal sold 186 shares of Penumbra common stock at a price of $312.64 per share under a pre-arranged Rule 10b5-1 trading plan. After this transaction, Grewal directly beneficially owned 8,230 shares of Penumbra common stock.
Penumbra Inc. director Thomas C. Wilder reported a small sale of company stock. On 01/02/2026, he sold 186 shares of Penumbra common stock at a price of $310.72 per share, coded as a sale transaction. Following this trade, he no longer holds shares directly but continues to beneficially own 4,506 shares indirectly through the Thomas and Catharine Wilder Family Trust dated March 31, 2006.
The filing notes that the sale was carried out under a pre-established Rule 10b5-1 trading plan, which is designed to allow insiders to sell shares according to predetermined instructions.
Penumbra, Inc. insider Harpreet Grewal has filed a notice of proposed sale under Rule 144 for 186 shares of common stock, with an aggregate market value of 58,151.04. The shares are to be sold through Fidelity Brokerage Services LLC on the NYSE around January 6, 2026, and Penumbra has 39,162,177 shares of common stock outstanding.
The 186 shares to be sold were acquired as a stock award from Penumbra on December 31, 2025. Over the prior three months, the same seller disposed of 186 shares on November 4, 2025 for 42,329.88 and 100 shares on December 2, 2025 for 29,298.00. By signing the notice, the seller represents that they do not know of any material adverse, nonpublic information about Penumbra’s operations.
A holder of PEN common stock has filed a notice to potentially sell shares under Rule 144. The filing covers the planned sale of 186 common shares through Morgan Stanley Smith Barney LLC Executive Financial Services on the NYSE, with an indicated aggregate market value of $57,793.92. The issuer had 39,162,177 shares outstanding at the time referenced. The shares to be sold were acquired as restricted stock from the issuer on 12/31/2025, with payment also dated 12/31/2025.
Penumbra Inc's chief financial officer, Maggie Yuen, reported a tax-related share withholding tied to her equity compensation. On 12/15/2025, 565 shares of Penumbra common stock were withheld by the company at a price of $309.15 per share, identified with transaction code F for tax withholding.
After this transaction, Yuen beneficially owned 16,006 Penumbra shares, some of which remain subject to vesting. The total includes 15 shares purchased under Penumbra's Employee Stock Purchase Plan on November 19, 2025. The filing characterizes the withholding as satisfying tax obligations arising from the vesting of restricted stock units previously granted to her.
Penumbra’s chief accounting officer, Lambert Shiu, reported an insider transaction involving 300 shares of common stock on 12/15/2025. The 300 shares were withheld by the company to cover tax withholding obligations triggered by the vesting of restricted stock units previously granted to him.
After this transaction, Shiu beneficially owns 35,285 Penumbra common shares directly, with a portion of these shares still subject to vesting and including 20 shares purchased under the company’s Employee Stock Purchase Plan on November 19, 2025. He also indirectly owns 300 shares held in his spouse’s IRA.
Penumbra Inc. executive Johanna Roberts, EVP, General Counsel & Secretary, reported a tax-related share withholding tied to equity compensation. On 12/15/2025, 1,130 shares of Penumbra common stock were disposed of at $309.15 per share under transaction code F, which indicates shares withheld to satisfy tax obligations on vesting restricted stock units.
After this transaction, she beneficially owns 62,706 shares of Penumbra common stock, and a portion of these shares remains subject to vesting. No derivative securities transactions were reported.
Penumbra Inc. director Arani Bose reported multiple open-market sales of Penumbra common stock on 12/11/2025, carried out under a pre-arranged Rule 10b5-1 trading plan. The transactions, all coded as sales, were executed in several tranches, including 2,030 shares at a weighted average price of $305.19, 4,946 shares at $306.6, and 3,523 shares at $311.47, with other trades priced in the general range of $305–$312 per share.
Following one of the reported transactions, the filing shows 258,462 shares of Penumbra common stock beneficially owned indirectly through Bose Family Holdings II, LLC, and a portion of these shares is subject to vesting. The filing emphasizes that several trades were executed in multiple lots within stated price ranges, with the weighted average prices reported and full trade details available upon request.
Penumbra Inc. executive vice president, general counsel and secretary reported a small stock sale under a pre-arranged trading plan. On 12/05/2025, the reporting person sold 300 shares of Penumbra common stock at a weighted average price of $300.13 per share under a Rule 10b5-1 trading plan, which allows preset trades to occur over time. After this transaction, the insider beneficially owned 63,836 shares of Penumbra common stock, a portion of which remains subject to vesting.